Similar to TNF-α blockade, there has been increasing interest in the use of an IL-6 inhibitor (tocilizumab) as another attractive option with proven effectiveness for treatment of irAEs without having an impact on tumor response [3,38,39]. This evidence concerns the gene IL6 and neoplasm.